Icosavax Reports Positive 12-Month Durability Data for VLP Vaccine Candidate IVX-121 Against RSV and Initial Evidence for Revaccination Potential

Stock Information for Atento S.A.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Atento S.A.

Icosavax Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Icosavax to Participate in the Jefferies London Healthcare Conference
Icosavax to Participate in the Guggenheim Healthcare Talks 5th Annual Inflammation, Neurology & Immunology (INI) Conference
Icosavax to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023
Icosavax Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Icosavax Initiates Phase 2 Trial of IVX-A12 Against RSV and hMPV in Older Adults
Icosavax Announces $67.8 Million Registered Direct Offering of Common Stock
Icosavax Announces Positive Topline Interim Phase 1 Results for Bivalent VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.